uniQure N.V. (QURE)
NASDAQ: QURE
· Real-Time Price · USD
17.95
0.22 (1.24%)
At close: Sep 05, 2025, 3:59 PM
17.95
0.00%
After-hours: Sep 05, 2025, 06:54 PM EDT
1.24% (1D)
| Bid | 17.5 |
| Market Cap | 984.86M |
| Revenue (ttm) | 14.34M |
| Net Income (ttm) | -199M |
| EPS (ttm) | -3.9 |
| PE Ratio (ttm) | -4.6 |
| Forward PE | -5.45 |
| Analyst | Buy |
| Ask | 18.63 |
| Volume | 2,064,573 |
| Avg. Volume (20D) | 1,125,761 |
| Open | 17.92 |
| Previous Close | 17.73 |
| Day's Range | 17.37 - 18.15 |
| 52-Week Range | 4.45 - 19.18 |
| Beta | 0.13 |
About QURE
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol QURE
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for QURE stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsNext Earnings Release
uniQure N.V. is scheduled to release its earnings on
Nov 4, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+5.7%
Shares of several biotechnology stocks are trading...
Unlock content with
Pro Subscription
1 month ago
-8.68%
uniQure shares are trading lower after the company reported worse-than-expected Q2 sales results.
21 hours ago · seekingalpha.com
uniQure: Getting Nervous Ahead Of Critical Huntington's Gene Therapy DatauniQure's lead candidate AMT-130 targets Huntington's disease with promising clinical data and potential for accelerated FDA approval, driving my continued Buy rating. The company has strong cash rese...
1 month ago · fool.com
uniQure Narrows Loss in Fiscal Q2uniQure Narrows Loss in Fiscal Q2
